Skip to main content

Day: August 29, 2025

Ackermans & van Haaren: First-Half 2025 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Dear shareholder, Dear Madam, Dear Sir,Ackermans & van Haaren publishes today its Half-Year 2025 Results  Strong results of core participations support the growth of Ackermans & van Haaren’s H1 2025 profit to 273 million euros (+36%)Record half-year results at DEME, Delen Private Bank, Bank Van Breda and SIPEF Significant improvement of results at Nextensa Outlook (strengthened): net profit for the full-year 2025 is expected to increase by at least 15% Positive net cash position of 431 million eurosPlease find annexed the full press release. Best regards Ackermans & van HaarenAttachmentAvH First-Half 2025 Results – Press Release (20250829)

Continue reading

CoinShares Announces Q2 2025 Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

CoinShares Announces Q2 2025 Results 29th August 2025 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), the leading European asset manager specialising in digital assets, has today published its results for the quarter ending 30th June 2025. Q2 2025 Financial HighlightsAsset Management fees of $30.0 million (Q2 2024: $28.3 million) Capital Markets gains/income of $11.3 million (Q2 2024: $14.6 million) Adjusted EBITDA of $26.3 million (Q2 2024: $25.5 million*) Treasury gain of $7.8 million (Q2 2024: $0.4 million loss) Net profit of $32.4 million (Q2 2024: $31.8 million) EPS (basic) for Q2 2025 of $0.49 (Q2 2024: $0.47) Total comprehensive income of $33.0 million (Q2 2024: $32.6 million)*Presented exclusive of FTX claim sale income and FlowBank impairment Jean-Marie...

Continue reading

RomReal: Second quarter (q2) 2025 Results Report and Investor Presentation

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

RomReal hereby announces the results of the second quarter 2025 via the Report and an Investor presentation attached to this message. For further information, pls contact investors@romreal.comThis information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentsRomReal Q2 2025 PresentationRomReal Q2 2025 Report

Continue reading

American Rebel Holdings Clarifies: No Amended S-1 Filed on August 28; Webull/Benzinga Posts Mischaracterized Prior June 3 Filing

Written by Customer Service on . Posted in Public Companies.

After fielding multiple investor calls prompted by misleading August 28 Benzinga posts, the Company confirms no new S-1/A was filed; the referenced amendment was filed June 3, 2025, and the referenced registration was declared effective June 27, 2025. Nashville, TN, Aug. 28, 2025 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB; AREBW) (“American Rebel” or the “Company”) today issued a clarification regarding an erroneous August 28 media post that insinuated the Company was filing a new amended registration statement on Form S-1. A syndicated item on the Webull news feed reflected the same incorrect implication. The Company confirms that no amended S-1 was filed today and that any August 28 references to such action are inaccurate. This mischaracterization may have caused confusion among investors or triggered unnecessary...

Continue reading

Solar Alliance Announces Resumption of TSXV Trading, Corporate Update

Written by Customer Service on . Posted in Public Companies.

TORONTO and KNOXVILLE, Tenn., Aug. 28, 2025 (GLOBE NEWSWIRE) — Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR, OTC: SAENF), a leading solar energy solutions provider focused on the commercial and utility solar sectors, announces that trading of its common shares will be reinstated on the TSX Venture Exchange (“TSXV“) at the opening of the market on or about September 3, 2025. This follows the successful resolution of the cease trade order issued by the British Columbia Securities Commission (“BCSC“) on May 7, 2025 and revoked by the BCSC on May 22, 2025. The Company acknowledges and appreciates the patience of its shareholders during this process and reaffirms its commitment to adhering to high standards of compliance and corporate governance. Industry and Corporate Update Background The...

Continue reading

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Financial Results and Operational Update for the Full Year Ended June 30, 2025 NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. Mesoblast Chief Executive Dr. Silviu Itescu said, “This has been a banner year for the Company, with achievement of FDA approval for Ryoncil®, the first and only FDA approved mesenchymal stromal cell (MSC) product in the United States and a successful commercial launch of the product for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older (“children”).” ”We are working tirelessly to transform Mesoblast into a fast-paced commercial biotechnology...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.